LBCA has developed an ILC Advocacy Toolkit. Our goal is to empower interested patients, caregivers, clinicians, and researchers to join our efforts to educate others about ILC and support ILC research.
Please check back for regular updates to this toolkit.
Information on Lobular Breast Cancer can be hard to find in traditional breast cancer institutions and organizations. You can help educate others about lobular breast cancer and raise awareness in your local cancer community. Get tips on how....
Research advocacy focuses on involving advocates in cancer research to make sure research reflects patient needs and outcomes. A research advocate can be a patient, caregiver, survivor or co-survivor who is interested in the science behind breast cancer research....
Susan G. Komen Advocates in Science hosted a webinar geared towards research advocate in their Advocates in Science program and new advocates interested in lobular advocacy. Learn about Komen’s Advocates in Science and watch the webinar.
LBCA advocates presented a webinar with SHARE Cancer Support that included an overview of patient advocacy and how to get involved.
The links below contain educational information and printable materials that can be downloaded and used as handouts at conferences, meetings or events.
Signs of Invasive Lobular Breast Cancer in the Breast. Lobular Breast Cancer is often not a lump. Learn more about changes in the breast that can mean lobular breast cancer...
LBCA's Frequently Asked Questions (FAQs) is designed for patients, caregivers and others interested in more information about Lobular Breast Cancer. ...
Susan G. Komen partnered with the Lobular Breast Cancer Alliance to host a webinar Lobular Breast Cancer: A Different Disease. This webinar is geared towards established research advocates and those interested in learning about advocacy. This webinar is presented by Steffi Oesterreich, PhD Komen Scholar......
Please join LBCA to educate about the Signs of Lobular Breast Cancer – the second most common cellular type of breast cancer that is the 6th most frequently diagnosed cancer of women in the U.S. Help spread the word with your networks and raise awareness......
The Lobular Breast Cancer Alliance partnered with SHARE Cancer Support to host an advocate-led roundtable discussion on August 28th, 2019. This hour-long webinar features LBCA advocates and lobular patients Leigh Pate and Elizabeth Viggiano discussing unique aspects of lobular breast cancer and the role of......
One of the most important ways a patient can advocate for their own care is to learn about their disease. There are many organizations and websites available to help patients learn more about breast cancer. ...
Invasive Lobular Breast Cancer is the sixth most diagnosed cancer of women in the US. Recent research has highlighted opportunities to better understand this disease and improve the diagnosis, treatment and follow-up care for thousands of patients with ILC....
Please spread the word about the Lobular Breast Cancer Alliance by downloading and printing LBCA materials for conferences, meetings and events....
May, 2020 by Priscilla F. McAuliffe MD PhD, Beth Z. Clark MD, Jennifer M. Xavier PhD, Steffi Oesterreich PhD, Rachel C. Jankowitz MD The unprecedented COVID-19 pandemic has challenged many aspects of breast cancer care, particularly with respect to oncology clinical trials. A recent survey......
Postmenopausal women who have been diagnosed with invasive lobular breast cancer (ILC) who have not yet had surgery to remove their tumor may be eligible to participate in a multi-site clinical trial. This clinical trial will compare how lobular breast tumors respond to three different commonly prescribed, effective medications that are currently being used to treat breast cancer. ...
Patients with Metastatic Lobular Breast Cancer (cancer has spread beyond the breast to other parts of the body) have a unique opportunity to advance critical research by participating in the Metastatic Breast Cancer Project's ILC initiative....
Women who have been diagnosed with Stage 1 - 3 invasive lobular breast cancer (ILC) who have not yet had surgery to remove their tumor may be eligible to participate in a clinical trial. This trial is open to all ER+ and/or PR+ HER2- patients (ductal or lobular), however it is being enriched with lobular breast cancer patients to promote a better understanding of how ILC might respond differently to these therapies....